88 related articles for article (PubMed ID: 9815807)
21. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
22. Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.
Kroger LA; DeNardo SJ; DeNardo GL; Xiong CY; Winthrop MD; Gumerlock PH
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3010s-3014s. PubMed ID: 10541336
[TBL] [Abstract][Full Text] [Related]
23. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
24. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia.
Jaksic O; Vrhovac R; Kusec R; Kardum MM; Pandzic-Jaksic V; Kardum-Skelin I; Planinc-Peraica A; Morabito F; Brugiatelli M; Jaksic B
Haematologica; 2001 Aug; 86(8):827-36. PubMed ID: 11522539
[TBL] [Abstract][Full Text] [Related]
25. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
Domingo-Domènech E; Domingo-Clarós A; Gonzàlez-Barca E; Beneitez D; Alonso E; Romagosa V; De Sanjos S; Petit J; Grañena A; Fernández de Sevilla A
Haematologica; 2002 Oct; 87(10):1021-7. PubMed ID: 12368155
[TBL] [Abstract][Full Text] [Related]
26. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T; Gaya AM; Dancey G; Stratford MR; Othman S; Sharma SK; Wellsted D; Taylor NJ; Stirling JJ; Poupard L; Folkes LK; Chan PS; Pedley RB; Chester KA; Owen K; Violet JA; Malaroda A; Green AJ; Buscombe J; Padhani AR; Rustin GJ; Begent RH
Clin Cancer Res; 2009 Jul; 15(13):4484-92. PubMed ID: 19549771
[TBL] [Abstract][Full Text] [Related]
29. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.
Mirick GR; O'Donnell RT; DeNardo SJ; Shen S; Meares CF; DeNardo GL
Nucl Med Biol; 1999 Oct; 26(7):841-5. PubMed ID: 10628566
[TBL] [Abstract][Full Text] [Related]
30. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
31. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
Villela L; López-Guillermo A; Montoto S; Rives S; Bosch F; Perales M; Ferrer A; Esteve J; Colomo L; Campo E; Montserrat E
Cancer; 2001 Apr; 91(8):1557-62. PubMed ID: 11301405
[TBL] [Abstract][Full Text] [Related]
32. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Eton DT; Fairclough DL; Cella D; Yount SE; Bonomi P; Johnson DH;
J Clin Oncol; 2003 Apr; 21(8):1536-43. PubMed ID: 12697878
[TBL] [Abstract][Full Text] [Related]
33. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.
Iten F; Muller B; Schindler C; Rasch H; Rochlitz C; Oertli D; Maecke HR; Muller-Brand J; Walter MA
Cancer; 2009 May; 115(10):2052-62. PubMed ID: 19280592
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
35. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
36. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases.
Lv Y; Cheung NK; Fu BM
J Nucl Med; 2009 Aug; 50(8):1324-31. PubMed ID: 19617331
[TBL] [Abstract][Full Text] [Related]
37. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
Graff-Baker A; Roman SA; Thomas DC; Udelsman R; Sosa JA
Surgery; 2009 Dec; 146(6):1105-15. PubMed ID: 19958938
[TBL] [Abstract][Full Text] [Related]
39. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
40. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
